ID
4282
Description
The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer
Keywords
Versions (1)
- 12/6/13 12/6/13 - Martin Dugas
Uploaded on
December 6, 2013
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0 Legacy
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility DRKS00004052 NCT00661609 Advanced Bladder Cancer
Eligibility
- StudyEvent: Eligibility
Description
Exclusion criteria
Alias
- NCI Metathesaurus CUI
- C0680251
Description
Prior treatment
Data type
boolean
Alias
- NCI Metathesaurus CUI
- C1522449
- NCI Metathesaurus CUI
- C0949266
Description
Bone marrow
Data type
boolean
Alias
- NCI Metathesaurus CUI
- C0005953
Description
Liver function
Data type
boolean
Alias
- NCI Metathesaurus CUI
- C0232744
Description
Renal function
Data type
boolean
Alias
- NCI Metathesaurus CUI
- C0341697
Similar models
Eligibility
- StudyEvent: Eligibility
C0949266 (NCI Metathesaurus CUI)